A Phase 1 interventional study of Lenacapavir and Placebo in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 12 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-04-09.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objectives of this study are:
Part A: To evaluate the short-term antiviral activity of lenacapavir (formerly GS-6207) with respect to the maximum reduction of plasma HIV-1 RNA (log10 copies/mL) from Day 1 through Day 10 compared to placebo in HIV-1 infected adults who are antiretroviral treatment naive or are experienced but capsid inhibitor (CAI) naive.
Part B: To evaluate the short-term antiviral activity of tenofovir alafenamide (TAF) with respect to the maximum reduction of plasma HIV-1 RNA (log10 copies/mL) from Day 1 through Day 10 in HIV-1 infected adult subjects who are antiretroviral treatment naïve or are experienced but without resistance to TAF.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single dose of lenacapavir 20 mg on Day 1 followed by bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) as per standard-care therapy starting on Day 10 through Day 225.
Drug: Lenacapavir · Drug: B/F/TAF
Participants will receive single dose of lenacapavir 50 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
Drug: Lenacapavir · Drug: B/F/TAF
Participants will receive single dose of lenacapavir 150 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
Drug: Lenacapavir · Drug: B/F/TAF
Participants will receive single dose of lenacapavir 450 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
Drug: Lenacapavir · Drug: B/F/TAF
Participants will receive single dose of lenacapavir 750 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
Drug: Lenacapavir · Drug: B/F/TAF
Participants will receive single dose of placebo matched to lenacapavir on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
Drug: Placebo · Drug: B/F/TAF
Participants will receive a single dose of TAF 200 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
Drug: B/F/TAF · Drug: TAF
Participants will receive a single dose of TAF 600 mg on Day 1 followed by B/F/TAF as per standard-care therapy starting on Day 10 through Day 225.
Drug: B/F/TAF · Drug: TAF
Administered subcutaneously in the abdomen
Also known as: GS-6207
Administered subcutaneously in the abdomen
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
50/200/25 mg tablets administered orally once daily
Also known as: Biktarvy®
Tablets administered orally
Part A and Part B: Maximum Reduction From Day 1 (Baseline) Through Day 10 in Plasma HIV-1 RNA
Maximum reduction is defined as the minimum of change from baseline in plasma HIV-1 RNA (i.e. smallest change in HIV-RNA from baseline).
Time frame: Day 1 through Day 10
Part A and Part B: Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as any AE with an onset date on or after the study drug start date.
Time frame: Day 1 through 225 days
Part A and Part B: Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.
Time frame: Day 1 through 225 days
Part A and Part B Pharmacokinetic (PK) Parameter: AUCinf of Lenacapavir, TAF and Its Metabolite TFV
AUCinf is defined as area under the concentration versus time curve from time zero to infinity.
Time frame: Part A: 0 (predose),1,2,4,8,12,24 h postdose on Day 1, anytime on Days 3,4,7,8,9,10,14,29,43,57,85,113,141,169,197,225; Part B: 0 (predose),0.5,1,2,3,4,6,8,10,12,24 and 48 h postdose on Day 1, approximately Day 1 predose time on Days 4,5,6,7,8,9,10
Part A and Part B PK Parameter: AUClast of Lenacapavir, TAF and Its Metabolite TFV
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
Time frame: Part A: 0 (predose),1,2,4,8,12,24 h postdose on Day 1, anytime on Days 3,4,7,8,9,10,14,29,43,57,85,113,141,169,197,225; Part B: 0 (predose),0.5,1,2,3,4,6,8,10,12,24 and 48 h postdose on Day 1, approximately Day 1 predose time on Days 4,5,6,7,8,9,10
Part A and Part B PK Parameter: Cmax of Lenacapavir, TAF and Its Metabolite TFV
Cmax is defined as the maximum observed concentration of drug.
Time frame: Part A: 0 (predose),1,2,4,8,12,24 h postdose on Day 1, anytime on Days 3,4,7,8,9,10,14,29,43,57,85,113,141,169,197,225; Part B: 0 (predose),0.5,1,2,3,4,6,8,10,12,24 and 48 h postdose on Day 1, approximately Day 1 predose time on Days 4,5,6,7,8,9,10
Part B PK Parameter: AUCinf of TFV-DP Metabolite of TAF
AUCinf is defined as area under the concentration versus time curve from time zero to infinity.
Time frame: Part B: 0 (predose), 1, 2, 4, 6, 8, 12, 24 and 48 hours post dose on Day 1, approximately Day 1 predose time on Days 4, 5 (if possible), 6 (if possible), 7, 8, 9, 10
Part B PK Parameter: AUClast of TFV-DP Metabolite of TAF
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
Time frame: Part B: 0 (predose), 1, 2, 4, 6, 8, 12, 24 and 48 hours post dose on Day 1, approximately Day 1 predose time on Days 4, 5 (if possible), 6 (if possible), 7, 8, 9, 10
Part B PK Parameter: Cmax of TFV-DP Metabolite of TAF
Cmax is defined as the maximum observed concentration of drug.
Time frame: Part B: 0 (predose), 1, 2, 4, 6, 8, 12, 24 and 48 hours post dose on Day 1, approximately Day 1 predose time on Days 4, 5 (if possible), 6 (if possible), 7, 8, 9, 10
Part A: Percentage of Participants Ever Achieving HIV-1 RNA < 50 Copies/mL by Day 10
Time frame: Day 10
Part A: Number of Participants Experiencing Any Emergence of Capsid Inhibitor Resistance
Time frame: Day 10
Part A: Number of Participants Experiencing Any Emergence of Capsid Inhibitor Resistance
Post-Monotherapy Resistance Analysis Population analyzed for this outcome measure included any participant who received at least 1 dose of study drug/placebo, maintained their study drug regimen, \& met one of following virologic failure criteria: * HIV-1 RNA ≥ 50 copies/mL \& \< 1 log10 HIV-1 RNA reduction from Day 10 at Day 57 visit, confirmed at a scheduled or unscheduled visit at least 2 weeks following Day 57 * At any visit following Day 10, after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA to ≥ 50 copies/mL, which was subsequently confirmed at following scheduled or unscheduled visit; OR At any visit, a \> 1 log10 increase in HIV-1 RNA from nadir, which was subsequently confirmed at following scheduled or unscheduled visit; * Any participant with HIV-1 RNA ≥ 50 copies/mL at study endpoint or study discontinuation who didn't meet any of criteria above also had protease (PR)/reverse transcriptase (RT), integrase (IN), \&capsid (CA) genotyping \& phenotyping performed.
Time frame: Day 10 through Day 225
Part B: Number of Participants Experiencing Any Emergence of TAF Resistance
Time frame: Day 10
Part B: Number of Participants Experiencing Any Emergence of TAF Resistance
TAF Resistance testing was performed for any participant meeting Post-Monotherapy Resistance Analysis Population criteria - it included any participant who received at least 1 dose of study drug/placebo, maintained their study drug regimen, \& met one of the following virologic failure criteria: * HIV-1 RNA ≥50 copies/mL \& \< 1 log10 HIV-1 RNA reduction from D10 at the D57 visit, confirmed at scheduled or unscheduled visit at least 2 weeks following D57 * At any visit following D10, after achieving HIV-1 RNA\< 50 copies/mL, a rebound in HIV-1 RNA to ≥50 copies/mL, which was subsequently confirmed at the following scheduled/unscheduled visit; OR At any visit, a \> 1 log10 increase in HIV-1 RNA from nadir, which was subsequently confirmed at the following scheduled or unscheduled visit; * Any participant with HIV-1 RNA ≥50 copies/mL at study endpoint or study discontinuation who didn't meet any of the criteria above also had PR/RT, IN, and CA genotyping \& phenotyping performed. D = Day
Time frame: Day 10 through Day 225
Participants were enrolled at study sites in the United States. The first participant was screened on 26 November 2018. The last study visit occurred on 15 June 2020.
| Milestone | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: Tenofovir Alafenamide (TAF) 200 mg | Part B: TAF 600 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 7 | 6 | 6 | 10 | 7 | 5 |
| Completed | 6 | 6 | 6 | 5 | 5 | 10 | 7 | 5 |
| Not completed | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Enrolled but not treated | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
Maximum reduction is defined as the minimum of change from baseline in plasma HIV-1 RNA (i.e. smallest change in HIV-RNA from baseline).
| log10 copies/mL | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|---|---|---|---|---|---|
| Part A and Part B: Maximum Reduction From Day 1 (Baseline) Through Day 10 in Plasma HIV-1 RNA | -1.35 ± 0.318 | -1.79 ± 0.476 | -1.76 ± 0.203 | -2.20 ± 0.468 | -2.26 ± 0.662 | -0.17 ± 0.128 | -0.75 ± 0.270 | -0.91 ± 0.294 |
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. An AE could therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as any AE with an onset date on or after the study drug start date.
| percentage of participants | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|---|---|---|---|---|---|
| Part A and Part B: Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) | 83.3 | 100 | 83.3 | 100 | 80 | 70 | 85.7 | 100 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant.
| percentage of participants | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|---|---|---|---|---|---|
| Part A and Part B: Percentage of Participants Experiencing Treatment Emergent Laboratory Abnormalities | 83.3 | 83.3 | 100.0 | 66.7 | 100.0 | 80.0 | 100.0 | 80.0 |
AUCinf is defined as area under the concentration versus time curve from time zero to infinity.
| h*ng/mL | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|---|---|---|---|---|
| Part A: Lenacapavir | 6564.3 ± 2562.02 | 9124.1 ± 4443.03 | 31537.0 ± 6811.74 | 106041.1 ± 19939.41 | 181861.0 ± 73100.91 | — | — |
| Part B: TAF | — | — | — | — | — | 1270.3 ± 346.47 | 3556.1 ± 1396.81 |
| Part B: TFV | — | — | — | — | — | 2807.9 ± 904.23 | 13435.4 ± 1748.60 |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
| h*ng/mL | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|---|---|---|---|---|
| Part A: Lenacapavir | 5084.3 ± 2143.03 | 7524.4 ± 4140.40 | 28866.4 ± 8247.37 | 102919.0 ± 19984.50 | 171173.9 ± 80524.85 | — | — |
| Part B: TAF | — | — | — | — | — | 1265.8 ± 350.75 | 3553.0 ± 1396.14 |
| Part B: TFV | — | — | — | — | — | 2706.7 ± 877.05 | 12682.5 ± 1780.31 |
Cmax is defined as the maximum observed concentration of drug.
| ng/mL | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|---|---|---|---|---|
| Part A: Lenacapavir | 3.0 ± 1.00 | 5.4 ± 4.00 | 17.1 ± 7.33 | 60.1 ± 16.92 | 116.6 ± 40.38 | — | — |
| Part B: TAF | — | — | — | — | — | 1919.0 ± 822.57 | 3934.0 ± 742.85 |
| Part B: TFV | — | — | — | — | — | 93.0 ± 36.97 | 371.0 ± 72.76 |
AUCinf is defined as area under the concentration versus time curve from time zero to infinity.
| h*uM | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|
| Part B PK Parameter: AUCinf of TFV-DP Metabolite of TAF | 599.7 ± 299.36 | 7981.4 ± 3852.75 |
AUClast is defined as area under the concentration versus time curve from time zero to the last quantifiable concentration.
| h*uM | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|
| Part B PK Parameter: AUClast of TFV-DP Metabolite of TAF | 390.9 ± 372.31 | 7749.3 ± 3731.57 |
Cmax is defined as the maximum observed concentration of drug.
| uM | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|
| Part B PK Parameter: Cmax of TFV-DP Metabolite of TAF | 8.5 ± 9.94 | 163.0 ± 118.75 |
| percentage of participants | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo |
|---|---|---|---|---|---|---|
| Part A: Percentage of Participants Ever Achieving HIV-1 RNA < 50 Copies/mL by Day 10 | 0 | 16.7 | 0 | 16.7 | 20.0 | 0 |
| Participants | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo |
|---|---|---|---|---|---|---|
| Part A: Number of Participants Experiencing Any Emergence of Capsid Inhibitor Resistance | 1 | 1 | 0 | 0 | 0 | 0 |
Post-Monotherapy Resistance Analysis Population analyzed for this outcome measure included any participant who received at least 1 dose of study drug/placebo, maintained their study drug regimen, \& met one of following virologic failure criteria: * HIV-1 RNA ≥ 50 copies/mL \& \< 1 log10 HIV-1 RNA reduction from Day 10 at Day 57 visit, confirmed at a scheduled or unscheduled visit at least 2 weeks following Day 57 * At any visit following Day 10, after achieving HIV-1 RNA \< 50 copies/mL, a rebound in HIV-1 RNA to ≥ 50 copies/mL, which was subsequently confirmed at following scheduled or unscheduled visit; OR At any visit, a \> 1 log10 increase in HIV-1 RNA from nadir, which was subsequently confirmed at following scheduled or unscheduled visit; * Any participant with HIV-1 RNA ≥ 50 copies/mL at study endpoint or study discontinuation who didn't meet any of criteria above also had protease (PR)/reverse transcriptase (RT), integrase (IN), \&capsid (CA) genotyping \& phenotyping performed.
| Participants | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo |
|---|---|---|---|---|---|---|
| Part A: Number of Participants Experiencing Any Emergence of Capsid Inhibitor Resistance | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|
| Part B: Number of Participants Experiencing Any Emergence of TAF Resistance | 0 | 0 |
TAF Resistance testing was performed for any participant meeting Post-Monotherapy Resistance Analysis Population criteria - it included any participant who received at least 1 dose of study drug/placebo, maintained their study drug regimen, \& met one of the following virologic failure criteria: * HIV-1 RNA ≥50 copies/mL \& \< 1 log10 HIV-1 RNA reduction from D10 at the D57 visit, confirmed at scheduled or unscheduled visit at least 2 weeks following D57 * At any visit following D10, after achieving HIV-1 RNA\< 50 copies/mL, a rebound in HIV-1 RNA to ≥50 copies/mL, which was subsequently confirmed at the following scheduled/unscheduled visit; OR At any visit, a \> 1 log10 increase in HIV-1 RNA from nadir, which was subsequently confirmed at the following scheduled or unscheduled visit; * Any participant with HIV-1 RNA ≥50 copies/mL at study endpoint or study discontinuation who didn't meet any of the criteria above also had PR/RT, IN, and CA genotyping \& phenotyping performed. D = Day
No measurements were reported for this outcome.
Collected over Day 1 through 225 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Lenacapavir 20 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part A: Lenacapavir 50 mg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Part A: Lenacapavir 150 mg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part A: Lenacapavir 450 mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Part A: Lenacapavir 750 mg | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| Part A: Placebo | 0/10 (0%) | 1/10 (10%) | 7/10 (70%) |
| Part B: TAF 200 mg | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Part B: TAF 600 mg | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Event | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|---|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/5 | 0/10 | 0/7 | 0/5 |
| Atrial fibrillationCardiac disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/5 | 0/10 | 0/7 | 0/5 |
| Coronary artery diseaseCardiac disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/5 | 0/10 | 0/7 | 0/5 |
| Non-cardiac chest painGeneral disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/5 | 0/10 | 0/7 | 0/5 |
| Small intestinal obstructionGastrointestinal disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/5 | 1/10 | 0/7 | 0/5 |
| Event | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg |
|---|---|---|---|---|---|---|---|---|
| Injection site painGeneral disorders | 0/6 | 4/6 | 4/6 | 4/6 | 4/5 | 3/10 | 0/7 | 0/5 |
| Injection site erythemaGeneral disorders | 1/6 | 1/6 | 4/6 | 2/6 | 2/5 | 1/10 | 0/7 | 0/5 |
| Upper respiratory tract infectionInfections and infestations | 0/6 | 0/6 | 0/6 | 4/6 | 0/5 | 0/10 | 1/7 | 2/5 |
| NauseaGastrointestinal disorders | 1/6 | 1/6 | 0/6 | 0/6 | 0/5 | 1/10 | 2/7 | 3/5 |
| HeadacheNervous system disorders | 2/6 | 0/6 | 0/6 | 1/6 | 0/5 | 2/10 | 2/7 | 3/5 |
| Injection site indurationGeneral disorders | 0/6 | 1/6 | 3/6 | 2/6 | 1/5 | 1/10 | 0/7 | 0/5 |
| Injection site noduleGeneral disorders | 0/6 | 1/6 | 1/6 | 2/6 | 2/5 | 0/10 | 0/7 | 0/5 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/6 | 0/6 | 2/6 | 1/6 | 0/5 | 1/10 | 0/7 | 2/5 |
| AnxietyPsychiatric disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/5 | 0/10 | 0/7 | 2/5 |
| NasopharyngitisInfections and infestations | 1/6 | 1/6 | 2/6 | 2/6 | 0/5 | 1/10 | 1/7 | 0/5 |
Safety Analysis Set included all participants who were randomized/enrolled and received at least 1 dose of study drug.
| Age, Continuous(years) | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 33 ± 4.4 | 36 ± 14.4 | 39 ± 11.5 | 36 ± 15.5 | 37 ± 17.7 | 29 ± 9.3 | 29 ± 8.7 | 40 ± 8.7 | 34 ± 11.5 |
| Sex: Female, Male(Participants) | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 1 | 0 | 2 | 1 | 0 | 0 | 4 |
| Male | 6 | 6 | 5 | 6 | 3 | 9 | 7 | 5 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 0 | 1 | 3 | 1 | 5 | 2 | 13 |
| Not Hispanic or Latino | 5 | 6 | 6 | 5 | 2 | 9 | 2 | 3 | 38 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Race — Asian | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 3 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Race — Black | 0 | 2 | 3 | 2 | 1 | 4 | 1 | 0 | 13 |
| Race — White | 4 | 3 | 2 | 4 | 3 | 5 | 5 | 5 | 31 |
| Race — Other | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 3 |
| HIV-1 RNA(log10 copies/mL) | Part A: Lenacapavir 20 mg | Part A: Lenacapavir 50 mg | Part A: Lenacapavir 150 mg | Part A: Lenacapavir 450 mg | Part A: Lenacapavir 750 mg | Part A: Placebo | Part B: TAF 200 mg | Part B: TAF 600 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 4.46 ± 0.428 | 4.44 ± 0.328 | 4.48 ± 0.161 | 4.52 ± 0.190 | 4.56 ± 0.305 | 4.50 ± 0.371 | 4.23 ± 0.621 | 4.97 ± 0.439 | 4.50 ± 0.403 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2018 to primary completion in Nov 2019, 11 months.
Results were first posted in Dec 2020, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenacapavir · Tenofovir alafenamide